<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:5pt Arial, sans-serif; }
 .font1 { font:6pt Arial, sans-serif; }
 .font2 { font:7pt Arial, sans-serif; }
 .font3 { font:8pt Arial, sans-serif; }
 .font4 { font:9pt Arial, sans-serif; }
 .font5 { font:10pt Arial, sans-serif; }
 .font6 { font:11pt Arial, sans-serif; }
 .font7 { font:14pt Arial, sans-serif; }
 .font8 { font:16pt Arial, sans-serif; }
 .font9 { font:23pt Arial, sans-serif; }
 .font10 { font:10pt Times New Roman, serif; }
 .font11 { font:31pt Times New Roman, serif; }

</style>
</head>
<body>
<div>
<p><span class="font11">J.P. Morgan</span></p>
</div><br clear="all">
<p><span class="font4">Completed 06 Sep 2016 04:50 PM HKT</span></p>
<p><span class="font4">Disseminated 07 Sep 2016 09:27 PM HKT</span></p>
<p><span class="font5">Asia Pacific Equity Research</span></p>
<p><span class="font4">07 September 2016</span></p>
<div><a name="caption1"></a>
<h2><a name="bookmark0"></a><span class="font9" style="font-weight:bold;"><a name="bookmark1"></a>Fosun Pharmaceutical - H</span></h2>
<p><span class="font7">Fully Integrated Healthcare Player with</span></p>
<p><span class="font7">Underappreciated Pipeline; Assume coverage with OW</span></p>
</div><br clear="all">
<div>
<h6><a name="bookmark2"></a><span class="font8" style="font-weight:bold;"><a name="bookmark3"></a>Overweight</span></h6>
<p><span class="font4">Previous: Not Rated</span></p>
<p><span class="font4" style="font-weight:bold;">2196.HK, 2196 HK</span></p>
<p><span class="font4">Price: HK$23.90</span></p>
</div><br clear="all">
<div>
<p><span class="font4" style="font-weight:bold;">Price Target: HK$28.00</span></p>
</div><br clear="all">
<div>
<p><span class="font5" style="font-weight:bold;">CHINA CONNECT</span></p>
</div><br clear="all">
<p><span class="font10">We assume coverage of Fosun Pharma-H with an OW rating and HK$28.00 PT -from OW rating and Dec-15 HK$35.80 PT prior to NR designation - given its integrated healthcare platform, fast-growing hospital network, optimized pharmaceutical product portfolio through R&amp;D and further upside potential from M&amp;A. Trading at 15x 2017 P/E, we believe valuation does not reflect its full growth potential.</span></p>
<div>
<p><span class="font4" style="font-weight:bold;">China Healthcare Isabella Y. Zhao, CFA <sup>AC </sup></span><span class="font3">(852) 2800-8534 </span><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font3">isabella.zhao@jpmorgan.com</span></a></p>
<p><span class="font4" style="font-weight:bold;">Joanne Cheung </span><span class="font3">(852) 2800-8596 </span><a href="mailto:joanne.cy.cheung@jpmorgan.com"><span class="font3">joanne.cy.cheung@jpmorgan.com</span></a><span class="font3"> J.P. Morgan Securities (Asia Pacific) Limited</span></p>
</div><br clear="all">
<ul style="list-style:none;"><li>
<p><span class="font10" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Fully integrated business model with synergies: </span><span class="font10">Fosun Pharm is a premium healthcare giant with business covering all of the value chain. We project a healthy 16.5%/17% top/bottomline organic CAGR, 2015-2018, in line with street consensus, given: 1) increasing energies and leverage through all business segments; 2) rapid expansion of hospital network; 3) faster ramp up of medical devices such as Do Vinci surgical robot, IVD regents etc. 4) international markets expansion; 5) further upside from potential M&amp;A.</span></p>
<div>
</div><br clear="all"></li>
<li>
<p><span class="font10" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Accelerating hospital expansion: </span><span class="font10">Fosun is a pioneer in China’s large and fastgrowing private hospital market, supported by its proven track record of acquisitions. Fosun has total 3,018 beds in operation. We expect the number of beds to rise by at least 20% CAGR by acquisition of both private and public hospitals.</span></p></li>
<li>
<p><span class="font10" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Evolving R&amp;D pipeline: </span><span class="font10">Fosun spends 5% of pharma sales on R&amp;D, above industry average of 2-3% and has more than 172 pipeline projects with the industry’s most complete portfolio of biosimliar drugs and high entry barrier generic drugs; all supporting long term growth potential, in our view.</span></p></li>
<li>
<p><span class="font10" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Valuation </span><span class="font10">Our Dec-17 DCF-based PT is HK$28.0, implying 24% upside potential, or 17x our 2017 P/E. We believe Fosun deserves multiple expansion on its accelerated R&amp;D development &amp;&nbsp;upside from overseas acquisitions. </span><span class="font10" style="font-weight:bold;">Risks: </span><span class="font10">1) higher than expected tender price cut, 2) failure to gain from M&amp;A transactions, 3) delayed or failure of pipeline.</span></p></li></ul>
<p><span class="font4" style="font-weight:bold;">Fosun Pharmaceutical - H (Reuters: 2196.HK, Bloomberg: 2196 HK)</span></p>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">Rmb in mn, year-end Dec</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">FY12A</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">FY13A</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">FY14A</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">FY15A</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">FY16E</span></p></td><td colspan="2" style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">Company Data</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2">Revenue (Rmb mn)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">7,278</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">9,921</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">11,938</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">12,502</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">14,579</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">Shares O/S (mn)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2,379</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2">Net Profit (Rmb mn)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">1,564</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">1,583</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2,113</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2,460</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2,801</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">Market Cap (Rmb mn)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">48,978</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">EPS (Rmb)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.80</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.71</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.92</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.06</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.21</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Market Cap ($ mn)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">7,331</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">DPS (Rmb)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.25</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.32</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.34</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.39</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.44</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Price (HK$)</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">23.90</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">Revenue growth (%)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">13.1%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">36.3%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">20.3%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">4.7%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">16.6%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Date Of Price</span></p></td><td style="vertical-align:top;">
<p><span class="font2">05 Sep 16</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">EPS growth (%)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">30.3%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">(11.5%)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">30.3%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">15.6%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">14.0%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Free FI oat (%)</span></p></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">ROCE</span></p></td><td style="vertical-align:top;">
<p><span class="font2">2.9%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">4.7%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">4.5%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">4.6%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">5.1%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">3M - Avg daily vol (mn)</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">2.13</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">ROE</span></p></td><td style="vertical-align:top;">
<p><span class="font2">13.5%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">11.0%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">13.2%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">14.2%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">14.4%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">3M - Avg daily val (HK$ mn)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">42.62</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">P/E (x)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">25.8</span></p></td><td style="vertical-align:top;">
<p><span class="font2">29.1</span></p></td><td style="vertical-align:top;">
<p><span class="font2">22.4</span></p></td><td style="vertical-align:top;">
<p><span class="font2">19.3</span></p></td><td style="vertical-align:top;">
<p><span class="font2">17.0</span></p></td><td style="vertical-align:top;">
<p><span class="font2">3M - Avg daily val ($ mn)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">5.5</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">P/BV (x)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">3.0</span></p></td><td style="vertical-align:top;">
<p><span class="font2">3.0</span></p></td><td style="vertical-align:top;">
<p><span class="font2">2.8</span></p></td><td style="vertical-align:top;">
<p><span class="font2">2.6</span></p></td><td style="vertical-align:top;">
<p><span class="font2">2.3</span></p></td><td style="vertical-align:top;">
<p><span class="font2">MSCICNX-HLTH</span></p></td><td style="vertical-align:top;">
<p><span class="font2">146.86</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">EV/EBITDA (x)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">57.5</span></p></td><td style="vertical-align:top;">
<p><span class="font2">34.4</span></p></td><td style="vertical-align:top;">
<p><span class="font2">29.9</span></p></td><td style="vertical-align:top;">
<p><span class="font2">24.6</span></p></td><td style="vertical-align:top;">
<p><span class="font2">20.6</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Exchange Rate</span></p></td><td style="vertical-align:top;">
<p><span class="font2">776</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">Dividend Yield</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.2%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.5%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.6%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1.9%</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">2.1%</span></p></td><td style="vertical-align:top;">
<p><span class="font2">Price Target End Date</span></p></td><td style="vertical-align:top;">
<p><span class="font2">31-Dec-17</span></p></td></tr>
<tr><td colspan="2" style="vertical-align:top;">
<p><span class="font2">Source: Company data, Bloomberg, J.P. Morgan estimates.</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font2">Price Target (HK$)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">28.00</span></p></td></tr>
</table>
<p><span class="font4" style="font-weight:bold;">See page 33 for analyst certification and important disclosures, including non-US analyst disclosures.</span></p>
<p><span class="font10">J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.</span></p>
<p><a href="http://www.jpmorganmarkets.com"><span class="font6">www.jpmorganmarkets.com</span></a></p>
</body>
</html>